Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

10x Genomics (TXG) Return on Capital Employed (2019 - 2025)

Historic Return on Capital Employed for 10x Genomics (TXG) over the last 7 years, with Q4 2025 value amounting to 0.07%.

  • 10x Genomics' Return on Capital Employed rose 1700.0% to 0.07% in Q4 2025 from the same period last year, while for Dec 2025 it was 0.07%, marking a year-over-year increase of 1700.0%. This contributed to the annual value of 0.07% for FY2025, which is 1600.0% up from last year.
  • 10x Genomics' Return on Capital Employed amounted to 0.07% in Q4 2025, which was up 1700.0% from 0.11% recorded in Q3 2025.
  • In the past 5 years, 10x Genomics' Return on Capital Employed ranged from a high of 0.06% in Q4 2021 and a low of 0.64% during Q1 2021
  • Its 5-year average for Return on Capital Employed is 0.25%, with a median of 0.21% in 2023.
  • Within the past 5 years, the most significant YoY rise in 10x Genomics' Return on Capital Employed was 5600bps (2021), while the steepest drop was -5500bps (2021).
  • 10x Genomics' Return on Capital Employed (Quarter) stood at 0.06% in 2021, then plummeted by -226bps to 0.19% in 2022, then tumbled by -68bps to 0.32% in 2023, then rose by 25bps to 0.24% in 2024, then soared by 71bps to 0.07% in 2025.
  • Its last three reported values are 0.07% in Q4 2025, 0.11% for Q3 2025, and 0.12% during Q2 2025.